Zura Bio AI Stock Analysis
Want to see ZURA full AI Analyst Report?
Zura Bio (ZURA) AI Stock Analysis
Zura Bio
(NASDAQ:ZURA)
The score is driven down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and bearish technicals (price well below key moving averages with negative MACD). Corporate events add additional risk due to a Phase 2 trial miss and program discontinuation, partially tempered by the company’s debt-free balance sheet and stated cash runway.
Zura Bio (ZURA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $89.63M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.47M
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.86
- Revenue Growth
- ―
- EPS Growth
- -76.37%
- Country
- US
- Employees
- 40
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Zura Bio Business Overview & Revenue Model
Company Description
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα...
Zura Bio Financial Statement Overview
Summary
Financial profile is weak overall: no revenue, widening net losses in TTM, and deeply negative operating/free cash flow indicating significant cash burn. The main offset is a strong leverage position with zero reported debt and positive equity, which reduces near-term solvency risk but does not remove ongoing funding/runway pressure.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -16.00K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -94.76M | -68.60M | -52.39M | -60.56M | -27.33M | 8.42M |
| Net Income | -93.53M | -68.65M | -52.40M | -60.36M | -25.74M | 8.42M |
Balance Sheet | ||||||
| Total Assets | 194.63M | 113.95M | 179.53M | 100.84M | 5.26M | 140.55M |
| Cash, Cash Equivalents and Short-Term Investments | 187.65M | 109.41M | 176.50M | 99.81M | 1.57M | 729.22K |
| Total Debt | 0 | 0 | 0 | 0 | 7.76M | 0 |
| Total Liabilities | 16.97M | 12.41M | 19.51M | 21.29M | 27.32M | 10.35M |
| Stockholders Equity | 177.66M | 101.54M | 146.81M | 59.33M | -32.06M | 130.20M |
Cash Flow | ||||||
| Free Cash Flow | -81.69M | -64.93M | -28.15M | -23.05M | -13.20M | -1.10M |
| Operating Cash Flow | -81.60M | -64.81M | -28.08M | -15.05M | -1.20M | -1.10M |
| Investing Cash Flow | -90.00K | -113.00K | -5.08M | -8.00M | -12.00M | -139.38M |
| Financing Cash Flow | 130.32M | -2.16M | 109.84M | 121.29M | 14.77M | 141.21M |
Zura Bio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 2.57, below the 50-day MA of 3.54, and below the 200-day MA of 4.95, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 24.25 is Positive, neither overbought nor oversold. The STOCH value of 2.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZURA.
Zura Bio Risk Analysis
Zura Bio disclosed 82 risk factors in its most recent earnings report. Zura Bio reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksZura Bio Peers Comparison
Overall Rating
PBYI70Outperform
VOR44.8Neutral
ZURA43Neutral
CLLS42Neutral
PRQR39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | $368.09M | 14.80 | 17.52% | ― | 9.35% | -37.15% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $1.14B | 0.06 | -830.38% | ― | ― | ― | |
| 43Neutral | $91.74M | -0.83 | -53.97% | ― | ― | -76.37% | |
| 42Neutral | $77.77M | -0.79 | -319.92% | ― | -66.55% | -279.52% | |
| 39Underperform | $148.18M | -2.47 | -70.45% | ― | 40.51% | 2.98% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ZURA | Zura Bio Limited | 0.93 | -2.81 | -75.13% | |
| PBYI | Puma Biotechnology | 7.05 | 2.07 | 41.57% | |
| PRQR | ProQR Therapeutics BV | 1.04 | -1.16 | -52.73% | |
| CLLS | Cellectis S.A. | 0.92 | -4.43 | -82.80% | |
| VOR | Vor Biopharma, Inc. | 19.19 | 10.83 | 129.55% |
Zura Bio Corporate Events
Zura Bio Discontinues Hidradenitis Suppurativa Development After Trial Miss
NegativeOn November 9, 2026, Zura Bio reported that its Phase 2 TibuSHIELD trial of tibulizumab in adults with moderate-to-severe hidradenitis suppurativa did not meet its primary endpoint or key secondary endpoints. In the 247-participant study, abscess and...
Zura Bio Highlights Q3 Results and Tibulizumab Progress
PositiveOn October 27, 2026, Zura Bio reported third quarter 2026 financial results and detailed progress across its tibulizumab clinical programs, underscoring momentum in its pipeline for serious autoimmune and inflammatory diseases. The company said Phase...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
